DE3249568A1 - Glykoverwandtes antigen, verfahren zu dessen herstellung und dessen verwendung zur bekaempfung von krebs - Google Patents

Glykoverwandtes antigen, verfahren zu dessen herstellung und dessen verwendung zur bekaempfung von krebs

Info

Publication number: DE3249568A1
Authority: DE; Germany
Prior art keywords: gra; lectin; cancer; cells; related antigen
Prior art date: 1981-10-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

DE19823249568

Other languages

German (de)

English (en)

Other versions

DE3249568C2 (no

Inventor

Masakazu Takasaki Adachi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Otsuka Pharmaceutical Co Ltd

Original Assignee

Otsuka Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-10-01

Filing date

1982-09-30

Publication date

1985-02-07

1981-10-01 Priority claimed from JP56156413A external-priority patent/JPS5857318A/ja

1981-10-01 Priority claimed from JP15641481A external-priority patent/JPS5857321A/ja

1981-10-05 Priority claimed from JP56158473A external-priority patent/JPS5859923A/ja

1981-10-05 Priority claimed from JP56158472A external-priority patent/JPS5859922A/ja

1982-06-28 Priority claimed from JP57111168A external-priority patent/JPS591420A/ja

1982-09-30 Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd

1985-02-07 Publication of DE3249568A1 publication Critical patent/DE3249568A1/de

1987-10-01 Application granted granted Critical

1987-10-01 Publication of DE3249568C2 publication Critical patent/DE3249568C2/de

Status Granted legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 101
201000011510 cancer Diseases 0.000 title claims abstract description 91
239000000427 antigen Substances 0.000 title claims abstract description 21
102000036639 antigens Human genes 0.000 title claims abstract description 21
108091007433 antigens Proteins 0.000 title claims abstract description 21
238000000034 method Methods 0.000 title claims description 38
238000002360 preparation method Methods 0.000 title claims description 14
230000008569 process Effects 0.000 title claims description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 title abstract 6
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 title abstract 3
210000004027 cell Anatomy 0.000 claims abstract description 170
108090001090 Lectins Proteins 0.000 claims abstract description 49
102000004856 Lectins Human genes 0.000 claims abstract description 49
239000002523 lectin Substances 0.000 claims abstract description 49
210000000170 cell membrane Anatomy 0.000 claims abstract description 21
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims abstract description 19
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims abstract description 18
229930182830 galactose Natural products 0.000 claims abstract description 18
238000000265 homogenisation Methods 0.000 claims abstract description 4
108010046016 Peanut Agglutinin Proteins 0.000 claims description 12
239000002246 antineoplastic agent Substances 0.000 claims description 12
239000004480 active ingredient Substances 0.000 claims description 4
230000027455 binding Effects 0.000 claims description 4
238000005063 solubilization Methods 0.000 claims description 3
230000007928 solubilization Effects 0.000 claims description 3
239000012528 membrane Substances 0.000 claims description 2
101710186708 Agglutinin Proteins 0.000 claims 2
101710146024 Horcolin Proteins 0.000 claims 2
244000112675 Lablab purpureus Species 0.000 claims 2
101710189395 Lectin Proteins 0.000 claims 2
101710179758 Mannose-specific lectin Proteins 0.000 claims 2
101710150763 Mannose-specific lectin 1 Proteins 0.000 claims 2
101710150745 Mannose-specific lectin 2 Proteins 0.000 claims 2
239000000910 agglutinin Substances 0.000 claims 2
230000015572 biosynthetic process Effects 0.000 abstract description 7
208000033763 Familial hyperaldosteronism type I Diseases 0.000 description 209
201000011266 glucocorticoid-remediable aldosteronism Diseases 0.000 description 209
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
210000004698 lymphocyte Anatomy 0.000 description 35
241000699670 Mus sp. Species 0.000 description 30
238000012360 testing method Methods 0.000 description 23
239000000872 buffer Substances 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 21
108090000623 proteins and genes Proteins 0.000 description 21
239000002609 medium Substances 0.000 description 20
239000011780 sodium chloride Substances 0.000 description 20
241000699666 Mus <mouse, genus> Species 0.000 description 19
239000012980 RPMI-1640 medium Substances 0.000 description 17
108091003079 Bovine Serum Albumin Proteins 0.000 description 16
208000005718 Stomach Neoplasms Diseases 0.000 description 16
239000012894 fetal calf serum Substances 0.000 description 16
206010017758 gastric cancer Diseases 0.000 description 16
201000011549 stomach cancer Diseases 0.000 description 16
239000001963 growth medium Substances 0.000 description 15
239000012636 effector Substances 0.000 description 14
210000004989 spleen cell Anatomy 0.000 description 14
230000003013 cytotoxicity Effects 0.000 description 13
231100000135 cytotoxicity Toxicity 0.000 description 13
239000000243 solution Substances 0.000 description 13
229920002684 Sepharose Polymers 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 12
239000000203 mixture Substances 0.000 description 12
238000000926 separation method Methods 0.000 description 12
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
108010002350 Interleukin-2 Proteins 0.000 description 11
102000000588 Interleukin-2 Human genes 0.000 description 11
239000000126 substance Substances 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
206010006187 Breast cancer Diseases 0.000 description 10
208000026310 Breast neoplasm Diseases 0.000 description 10
210000002966 serum Anatomy 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
239000013504 Triton X-100 Substances 0.000 description 8
229920004890 Triton X-100 Polymers 0.000 description 8
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 8
230000000694 effects Effects 0.000 description 8
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 8
239000002504 physiological saline solution Substances 0.000 description 8
210000000952 spleen Anatomy 0.000 description 8
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 7
238000001042 affinity chromatography Methods 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
108010039433 dolichos biflorus agglutinin Proteins 0.000 description 7
239000007788 liquid Substances 0.000 description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
230000004913 activation Effects 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
208000011691 Burkitt lymphomas Diseases 0.000 description 5
239000012981 Hank's balanced salt solution Substances 0.000 description 5
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 5
206010058467 Lung neoplasm malignant Diseases 0.000 description 5
206010029260 Neuroblastoma Diseases 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
239000007853 buffer solution Substances 0.000 description 5
230000002147 killing effect Effects 0.000 description 5
201000005202 lung cancer Diseases 0.000 description 5
208000020816 lung neoplasm Diseases 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 5
238000010186 staining Methods 0.000 description 5
206010005003 Bladder cancer Diseases 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
238000001502 gel electrophoresis Methods 0.000 description 4
230000028993 immune response Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
210000001165 lymph node Anatomy 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
201000005112 urinary bladder cancer Diseases 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000003556 assay Methods 0.000 description 3
-1 bromoacetyl Chemical group 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 3
239000008101 lactose Substances 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
229960004857 mitomycin Drugs 0.000 description 3
230000004044 response Effects 0.000 description 3
230000001235 sensitizing effect Effects 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
101000934342 Mus musculus T-cell surface glycoprotein CD5 Proteins 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
230000002308 calcification Effects 0.000 description 2
230000005907 cancer growth Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
238000000576 coating method Methods 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000004040 coloring Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000013256 coordination polymer Substances 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
108010065337 fluorescein isothiocyanate-peanut agglutinin Proteins 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
230000005484 gravity Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229920001542 oligosaccharide Chemical group 0.000 description 2
150000002482 oligosaccharides Chemical group 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
108010086652 phytohemagglutinin-P Proteins 0.000 description 2
230000007505 plaque formation Effects 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
102000007563 Galectins Human genes 0.000 description 1
108010046569 Galectins Proteins 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
VLHUSFYMPUDOEL-WZTVWXICSA-N Iothalamate meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VLHUSFYMPUDOEL-WZTVWXICSA-N 0.000 description 1
241001507252 Japanese monkeys Species 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000009097 Phosphorylases Human genes 0.000 description 1
108010073135 Phosphorylases Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
101150052863 THY1 gene Proteins 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
239000011324 bead Substances 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
235000005770 birds nest Nutrition 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
230000005880 cancer cell killing Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
HBNYJWAFDZLWRS-UHFFFAOYSA-N ethyl isothiocyanate Chemical compound CCN=C=S HBNYJWAFDZLWRS-UHFFFAOYSA-N 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000013016 learning Effects 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
HFZNPKDYLSOGBE-SCEMAYBHSA-N nrc-12 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(C)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)C(C)C)[C@@H](C)O)C(C)C)C(C)C)C1=CC=C(O)C=C1 HFZNPKDYLSOGBE-SCEMAYBHSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
229940116357 potassium thiocyanate Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
235000005765 wild carrot Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

DE19823249568 1981-10-01 1982-09-30 Glykoverwandtes antigen, verfahren zu dessen herstellung und dessen verwendung zur bekaempfung von krebs Granted DE3249568A1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP56156413A JPS5857318A (ja)	1981-10-01	1981-10-01	癌細胞障害性リンパ球の製造法
JP15641481A JPS5857321A (ja)	1981-10-01	1981-10-01	抗癌剤
JP56158473A JPS5859923A (ja)	1981-10-05	1981-10-05	抗癌剤
JP56158472A JPS5859922A (ja)	1981-10-05	1981-10-05	癌細胞障害性リンパ球
JP57111168A JPS591420A (ja)	1982-06-28	1982-06-28	糖鎖関連抗原およびその製造法

Publications (2)

Publication Number	Publication Date
DE3249568A1 true DE3249568A1 (de)	1985-02-07
DE3249568C2 DE3249568C2 (no)	1987-10-01

Family

ID=27526479

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE19823249568 Granted DE3249568A1 (de)	1981-10-01	1982-09-30	Glykoverwandtes antigen, verfahren zu dessen herstellung und dessen verwendung zur bekaempfung von krebs
DE19823236298 Granted DE3236298A1 (de)	1981-10-01	1982-09-30	Krebszellen bekaempfende lymphocyten, verfahren zu deren herstellung und anti-krebsmittel, welche die lymphocyten enthalten

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE19823236298 Granted DE3236298A1 (de)	1981-10-01	1982-09-30	Krebszellen bekaempfende lymphocyten, verfahren zu deren herstellung und anti-krebsmittel, welche die lymphocyten enthalten

Country Status (19)

Country	Link
AR (1)	AR230731A1 (no)
AT (2)	AT382080B (no)
AU (1)	AU554858B2 (no)
BE (1)	BE893704A (no)
CA (1)	CA1195269A (no)
CH (2)	CH655660B (no)
DD (2)	DD209577A5 (no)
DE (2)	DE3249568A1 (no)
DK (1)	DK292182A (no)
FI (1)	FI77157C (no)
FR (1)	FR2513882B1 (no)
IL (1)	IL66270A (no)
IT (1)	IT1189305B (no)
MX (1)	MX7437E (no)
NL (1)	NL8202638A (no)
NO (1)	NO161601C (no)
NZ (1)	NZ201112A (no)
PT (1)	PT75148B (no)
SE (1)	SE8204058L (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60214737A (ja) *	1984-04-06	1985-10-28	Nippon Koutai Kenkyusho:Kk	糖鎖関連抗原の製造法
EP0334300A1 (en) *	1988-03-21	1989-09-27	Neorx Corporation	The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1193378A (en) *	1967-04-11	1970-05-28	Rand Dev Corp	Cancer Antigen Complexes
DE1943699A1 (de) *	1969-08-28	1971-03-04	Stiftung Onophrio	Heilmittel mit proliferationshemmender Wirkung und Verfahren zur Herstellung dieses Heilmittels
YU34005B (en) *	1970-02-24	1978-10-31	Podvinec Srecko	Process for obtaining bovine lymphatic gland extract
US4371515A (en) *	1978-12-26	1983-02-01	E-Y Laboratories, Inc.	Method for forming an isolated lectin-immunological conjugate

1982
- 1982-06-29 DK DK292182A patent/DK292182A/da not_active Application Discontinuation
- 1982-06-29 NZ NZ201112A patent/NZ201112A/en unknown
- 1982-06-29 PT PT75148A patent/PT75148B/pt not_active IP Right Cessation
- 1982-06-29 NO NO822215A patent/NO161601C/no unknown
- 1982-06-29 FI FI822325A patent/FI77157C/fi not_active IP Right Cessation
- 1982-06-30 AU AU85458/82A patent/AU554858B2/en not_active Ceased
- 1982-06-30 BE BE0/208493A patent/BE893704A/fr not_active IP Right Cessation
- 1982-06-30 AR AR289864A patent/AR230731A1/es active
- 1982-06-30 MX MX8210163U patent/MX7437E/es unknown
- 1982-06-30 CH CH398882A patent/CH655660B/de unknown
- 1982-06-30 FR FR8211489A patent/FR2513882B1/fr not_active Expired
- 1982-06-30 SE SE8204058A patent/SE8204058L/xx not_active Application Discontinuation
- 1982-06-30 DD DD82241290A patent/DD209577A5/de not_active IP Right Cessation
- 1982-06-30 NL NL8202638A patent/NL8202638A/nl not_active Application Discontinuation
- 1982-06-30 DD DD82261475A patent/DD221917A5/de not_active IP Right Cessation
- 1982-06-30 CH CH551284A patent/CH655661B/de unknown
- 1982-06-30 IT IT48724/82A patent/IT1189305B/it active
- 1982-07-08 IL IL66270A patent/IL66270A/xx unknown
- 1982-09-30 DE DE19823249568 patent/DE3249568A1/de active Granted
- 1982-09-30 DE DE19823236298 patent/DE3236298A1/de active Granted
- 1982-10-01 AT AT0363782A patent/AT382080B/de not_active IP Right Cessation
- 1982-10-01 CA CA000412670A patent/CA1195269A/en not_active Expired
1985
- 1985-12-09 AT AT0354585A patent/AT390002B/de not_active IP Right Cessation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Biochem.Biophys.Res.Comm., 62, 144, 1975, 89, 448-455, 1979, 96, 1547-1553, 1980 *
Biochemistry, 13, 196-204, 1974 *
Br.J.Exp.Pathol., 27, 228-236, 1946 *
Carbohydrate Research, 51, 107-118, 1976 *
Cell, 18, 183-191, 1979 *
J.B.C., 250, 8518-8523, 1975 *
J.Biochem., 89, 473-481, 1981 *
Proc.Nat.Acad.Sci., 75, 2215-2219, 1978 *
Z.Immunitätsforsch., 138, 423-433, 1966 *

Also Published As

Publication number	Publication date
PT75148A (en)	1982-07-01
AT382080B (de)	1987-01-12
DK292182A (da)	1983-04-02
IT1189305B (it)	1988-02-04
FR2513882B1 (fr)	1986-04-04
FI822325A0 (fi)	1982-06-29
FI77157B (fi)	1988-10-31
CH655661B (no)	1986-05-15
CH655660B (no)	1986-05-15
PT75148B (en)	1986-08-14
DE3249568C2 (no)	1987-10-01
NL8202638A (nl)	1983-05-02
AU554858B2 (en)	1986-09-04
NO161601C (no)	1989-09-06
ATA363782A (de)	1986-06-15
MX7437E (es)	1988-11-14
CA1195269A (en)	1985-10-15
IL66270A0 (en)	1982-11-30
ATA354585A (de)	1989-08-15
FI822325L (fi)	1983-04-02
AR230731A1 (es)	1984-06-29
FR2513882A1 (fr)	1983-04-08
NO161601B (no)	1989-05-29
IT8248724A0 (it)	1982-06-30
DE3236298C2 (no)	1987-09-24
AT390002B (de)	1990-03-12
DD209577A5 (de)	1984-05-16
SE8204058D0 (sv)	1982-06-30
IL66270A (en)	1986-03-31
AU8545882A (en)	1983-04-14
BE893704A (fr)	1982-10-18
FI77157C (fi)	1989-02-10
DD221917A5 (de)	1985-05-08
NO822215L (no)	1983-04-05
SE8204058L (sv)	1983-04-02
NZ201112A (en)	1986-10-08
DE3236298A1 (de)	1984-03-15

Legal Events

Date	Code	Title	Description
1985-02-07	AC	Divided out of	Ref country code: DE Ref document number: 3236298 Format of ref document f/p: P
1985-02-07	OP8	Request for examination as to paragraph 44 patent law
1987-09-24	AC	Divided out of	Ref country code: DE Ref document number: 3236298 Format of ref document f/p: P
1987-10-01	AC	Divided out of	Ref country code: DE Ref document number: 3236298 Format of ref document f/p: P
1987-10-01	D2	Grant after examination
1988-03-31	8364	No opposition during term of opposition
1992-09-10	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE3833319C2 (no)	1992-06-11
DE69125735T2 (de)	1997-09-04	Verfahren zur Aktivierung der zytolytischen Wirkung von Lymphozyten unter Verwendung von anti-CD28-Antikörper
US6051613A (en)	2000-04-18	Nitrogen monoxide production suppressor
WO1997017084A1 (de)	1997-05-15	Medikament, insbesondere zur modulation der immunantwort bei der bekämpfung von viren, tumoren, bakterien und parasiten
DE69725317T2 (de)	2004-07-29	Implantierbare agarose-kollagenkügelchen enthaltende zellen, die ein diffusionsfähiges biologisches produkt bilden und ihre verwendung
DE3812605A1 (de)	1990-06-07	Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
DE69014543T2 (de)	1995-06-22	Multivalentes immunogen lmi.
PT1289535E (pt)	2007-10-19	Entidades apoptóticas para utilização no tratamento de desordens neurodegenerativas e de outras desordens neurológicas
GB2106935A (en)	1983-04-20	Cancer cell-combatting lymphocytes process, for the production thereof, and anticancer agents containing said lymphocytes
DE60022499T2 (de)	2006-11-30	Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
DE3249568A1 (de)	1985-02-07	Glykoverwandtes antigen, verfahren zu dessen herstellung und dessen verwendung zur bekaempfung von krebs
DE69429657T2 (de)	2002-09-12	Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheiten
Alexander et al.	1971	Stimulants of cellular proliferation in wounds
CH643459A5 (de)	1984-06-15	Mikrobielles zellwandgeruest mit adjuvans- und antitumorwirkung enthaltende, verfestigte pharmazeutische zubereitung und ihre herstellung.
DE69527640T2 (de)	2003-04-24	Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten
DE3782996T2 (de)	1993-06-09	Zellmembranproteine, zubereitungen, die sie enthalten und verfahren zu ihrer herstellung.
EP0019167B1 (de)	1983-10-12	Arzneipräparat zur Behandlung von Carcinomen und Verfahren zu dessen Herstellung
Garcia-Giralt et al.	1973	Extraction From Bovine Spleen of Immunosuppressant With No Activity on Hematopoietic Spleen Colony Formation ¹
DE69433472T2 (de)	2004-11-25	Recognin-vakzine
Bolton	1905	On the production of a specific gastrotoxic serum.—Preliminary communication.
DE69430188T2 (de)	2002-10-31	Behandlung von hiv-infektionen mittels huminsäure
CA1201988A (en)	1986-03-18	Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes
KR880001758B1 (ko)	1988-09-12	암세포에 대항하는 임파구의 제조방법
US4877616A (en)	1989-10-31	Process for preparing xerosin II and xerosin III, improved biological response modifiers
DE102018113041A1 (de)	2019-01-24	Implantierbares pharmazeutisches Erzeugnis